reason report
bullish aducanumab interest even without
bottom line transfer coverag
team op rate sum-of-the-part sotp -base pt
invest thesi four-fold believ aducanumab
better chanc get approv earli alzheim diseas
ad becom signific product peak sale yet
stock reflect po valuat alreadi reflect worst
case scenario tecfidera loss exclus loe
signific spinraza declin due new competit durabl
royalti biosimilar remain underappreci provid
capit alloc option pipelin get minim attent
valu attribut thu good news portfolio drive
upsid valuat
svb leerink proprietari research underscor conclus
proprietari research report includ insight
medacorp physician interview page sotp
analys forecast key busi segment page
compani financi model page
price target pt base sotp analysi
forecast cash flow discount rate
acknowledg alzheim stori anyon
want talk right bottom line ultim
valu investor stock risk reward realli one best
seen larg cap name sinc bristol io radar mani
year ago stock upsid signific aducanumab get approv
believ investor would quickli sign peak sale
forecast take stock anoth also
win tecfidera patent case believ stock
without help rest pipelin import
real downsid protect analysi assum tecfidera
loe spinraza reach peak sale year declin
significantli sale get cut half competit
royalti roll middl decad attribut noth
pipelin see valuat support rang doesnt take
much glass half empti chang glass half full
realli like kind risk reward
risk invest thesi aducanumab approv
aducanumab face signific payer pushback new safeti signal
aducanumab practic hinder commerci uptak base busi
deterior worse-than-expect tecfidera gener entri happen
spinraza declin even faster forecast
early-stag pipelin product fail late-stag studi
link neurosci sector industri report
compani inform svb leerink llc research
revenu mm
sotp analysi forecast cash
flow discount
net debt total capit
price-to-earnings lt ep growth
year price history/av daili volume mil
pleas refer page import disclosur price chart analyst certif
initi outperform pt
bullish aducanumab interest even without
tabl content
invest thesi compani
invest thesi
thesi four-fold
believ aducanumab better chanc get approv earli alzheim diseas
becom signific product peak sale yet stock reflect po
valuat alreadi reflect worst case scenario tecfidera loe signific spinraza
declin due new competit
durabl base busi profit stream ms franchis royalti biosimilar remain
underappreci provid capit alloc option
pipelin get minim attent valu attribut thu good news portfolio drive
upsid valuat
pt base sotp analysi forecast cash flow discount rate
aducanumab approv fda
new safeti signal aducanumab detect practic hinder commerci uptak
base busi deterior worse-than-expect
tecfidera gener entri happen
spinraza declin even faster forecast
early-stag pipelin product fail late-stag studi
ms multipl sclerosi sma spinal muscular atrophi loe loss exclus po probabl success
compani focus neurolog autoimmun hematolog disord
found
ms franchis foundat base busi
sma near-term growth driver face
aducanumab could dmt approv
alzheim cautious optimist
regulatori approv commerci prospect
diversifi pipelin portfolio phase
phase phase program
timelin key near-term catalyst
earli nda file treat earli ad
phase opu data drug-resist focal epilepsi
phase affin data ms demyelin
phase spark data parkinson
late phase data choroideremia
late phase data acut ischem stroke
product non-risk adj revenu non-risk adj npv probabl successrisk-adj npv risk-adj net current valu share total tecfidera base eisai adj risk-adj risk-adj total asset count risk-adjust equiti valu exclud unalloc account corpor technolog franchis valu howev valu includ net cash adjust sotp valuat breakdown busi segmenttecfidera/vumerityg aadjustmentoth cashour pt inc
recent stock volatil mostli alzheim clinic data news
compani report svb leerink research factset data jan
valu
asset
loe
ocrevu us loe
item shown view sotp valuat note assum valu pipelin asset
scenario success would provid addit upsid
stock close jan po probabl success
compani report svb leerink estim except per share
ms demyelin
ad alzheim diseas xlrp x-link retin pigmentosa cia cognit impair associ schizophrenia al amyotroph later sclerosi
overview key debat
approv
peak sale
believ aducanumab good chanc get
approv drive peak sale given
signific unmet need believ fda want
approv dmt emerg well-control studi
show signific disease-modifi effect
despit protocol amend fail futil
analysi analysi engag
support condit approv fda may
requir confirmatori studi keep product
market dose respons
consist associ abeta/tau biomark
clinic respons trial safeti
profil also rel clean
durabl spinraza
face
competit
novarti roch
acknowledg risk agre
competit signific thu
base see materi competit
zolgensma risdiplam
durabl
think tecfidera face earli loe
upsid vumer thu limit model
assum see probabl worst case
loe gener competit
roughli correl appeal time frame
ipr district court case believ
sale ramp vumer would impact
compani report svb leerink research
risk
new safeti signal detect
studi ad approv
fda doesnt agre
data analysi method
want anoth pivot trial
approv product
faster forecast
alway possibl
launch risk
appeal process play
thu loe earlier
loe loss exclus
overview key debat
risk
durabl rest
ms franchis
durabl
market give
valu
pipelin
pipelin deserv
view franchis flat tail
profit stream probabl better expect
ms market crowd competit
lose share time new product
emerg gener entrant new pipelin asset
still earli key risk biosimilar
competit factor forecast
profil better
loe impact wors
pipelin product fail late-
think biosimilar provid
signific product ms space thu strong
royalti geograph
base product roll out well sever new biosimilar
launch help off-set increasingli competit
profil better
loe impact wors
fail deliv new product
think pipelin underappreci
pipelin product fail late-
get minim valu despit heavi focu
alzheim diversifi
pipelin mani high unmet need area
pipelin skew high-risk high-reward
asset seem disconnect
compar valuat mani smaller
innovation-bas compani
pipelin datapoint
end could chang investor percept
new product commerci
compani report svb leerink research
aducanumab fulli human monoclon antibodi
develop treatment alzheim
would dmt approv ad
signific clinic meaning treatment effect across multipl efficaci endpoint
clear dose respons abeta reduct diseas modif effect
gener well toler aria manag via titrat control
what
aducanumab select bind n-terminu aggreg form fibrillar oligomer
form reduc brain level
complet phase emerg engag studi
nda file expect
better effect subgroup
moa somewhat valid multipl anti-abeta antibodi fail treat ad aducanumab
competit dmt approv ad yet mani pipelin product develop
ad alzheim diseas psp supranuclear palsi csf cerebrospin fluid protocol version cdr-sb clinic dementia rate scale box
compani report public svb leerink estim
aducanumab get approv peak sale
get unexpect turnaround aducanumab phase studi
trial fail futil analysi emerg turn posit base larger data set analysi
patient
enrol engag vs
higher dose exposur
patient aria restart
carrier allow
titrat mg/kg
dose regimen adjust trial initi
engag initi
analysi data dec
stock significantli
emerg mix engag
result base larger data set
data march
regard turnaround think larger dataset result base popul valid support approv
regard mix engag data believ engag effect tamper sub-optimal dose exposur vs emerg
given enrol time patient enrol engag time chang
initi sub-optimal dose appli carrier due aria safeti concern
carrier titrat dose ensur enough exposur figur aria
could manag via care dose titrat therefor data readout complic modifi clinic design
compani report public ctad svb leerink research
aducanumab get approv peak sale
believ aducanumab data far support treatment effect earli ad
aducanumab show clear dose respons continu treatment effect time
month phase prime studi phase prime studi demonstr
consist trend across multipl outcom measur multipl subgroup provid larg
safeti databas think support approv
posit phase emerg studi confirm signific treatment effect higher
dose notabl aducanumab dose show reduct vs pbo
cdr-sb view clinic meaning physician show consist treatment
effect across multipl efficaci endpoint
phase engag patient enough exposur higher dose post
protocol chang show signific treatment effect consist prime
emerg believ phase engag result especi post-protocol-chang
subgroup also support aducanumab treatment effect despit mix data
treatment effect aducanumab well correl biomark chang substanti
dose-depend reduct abeta p-tau observ
aducanumab gener safe well toler aria advers event appear
manag titrat control
mmse mini-ment state exam cd-sb clinic dementia rate scale box adas-cog alzheim diseas assess scale-cognit subscal
adcs-adl alzheim diseas cooper studi activ daili live pbo placebo
signific unmet need ad fda understand issu
efficaci current symptom-treat drug limit
dmt approv ad
believ total aducanumab data packag support approv treat earli ad
aducanumab get approv peak sale
aducanumab show clear dose respons continu treatment effect
time phase prime studi prodromal/mild ad patient
rct dose-depend statist signific treatment effect abeta reduct cognit improv
dose-depend statist signific
posit long-term trend continu clinic benefit time month rct ole
pbo switch mg
aducanumab ole
aducanumab also show consist trend subgroup analysi across multipl outcom measur
believ safeti efficaci data prime support aducanumab long-term clinic benefit practic
compani report public ctad svb leerink research
mmse mini-ment state exam cdr-sb clinic dementia rate scale box
aducanumab get approv peak sale
phase emerg data confirm signific treatment effect
higher dose aducanumab observ prime studi
emerg show signific consist treatment effect across sever key efficaci endpoint
final data set base popul week
treatment effect aducanumab emerg continu time line prime data
treatment effect reduct cdr-sb
deem clinic meaning mani physician
mmse mini-ment state exam cdr-sb clinic dementia rate scale box adas-cog alzheim diseas assess scale-cognit subscal
adcs-adl alzheim diseas cooper studi activ daili live intent treat
compani report public ctad svb leerink research
aducanumab get approv peak sale
phase engag fail popul show signific
treatment effect popul support prime emerg
overal engag analysi show superior treatment benefit pbo
final data set base popul week
separ
pbo cdr-sb
dose fail separ
pbo key efficaci endpoint
pos-hoc analysi popul show compar efficaci engag vs emerg
popul effect cdr-sb
compani report public ctad svb leerink research
consist compar efficaci
cdr-sb clinic dementia rate scale box
aducanumab get approv peak sale
subgroup emerg engag exposur
higher dose enhanc treatment effect vs popul
caveat low dose arm impact
also show better effect subgroup
data base larger dataset final
neg percentag mean less progress treat arm
high dose arm studi show better treatment effect subgroup
median cumul dose emerge/engag combin week mg/kg vs
overal popul emerg engag
patient full dose mg/kg emerg engag vs
emerg engag overal popul patient emerg
patient engag
compani report public ctad svb leerink research
aducanumab get approv peak sale
treatment effect aducanumab well correl biomark chang
abeta tau provid addit data support diseas modif
magnitud abeta reduct line treatment effect treatment arm
treatment arm
engag sub-optimal abeta
reduct treatment effect due
trial also show signific reduct csf p-tau
show substanti
engag lower magnitud p-tau
reduct line lower treatment effect
signific treatment effect tau support aducanumab disease-modifi effect earli ad
compani report public ctad svb leerink research
aducanumab get approv peak sale
believ safeti profil aducanumab far support approv
aducanumab gener safe well toler
patient dose
aducanumab clinic trial
overal ae sae rate
aducanumab similar pbo arm
aria type
common
aria side effect appear manag titrat control mg/kg
aria event common
carrier therefor need
manag via titrat control
aria- tend occur earli
cours aducanumab treatment
gener could resolv
major patient aria
abl continu treatment
resolv advers event
major aria event
asymptomat case
compani report public ctad svb leerink research
aducanumab get approv peak sale
debat around saga think aducanumab data
agre data caveat multipl protocol amend fail futil analysi high dropout rate
non-prespecifi subset analysi unclear would includ label
believ protocol amend fail futil analysi distort final readout studi
base convers biostatistician ad specialist
believ fda allow use addit post-futil data march pre-plan
futil analysi break randomization/blind use pre-specified alpha
expect fda care examin increment patient post futil turn emerg neg
trend toward posit futil analysi posit assum patient
emerg remain well-control studi final analysi statist valid signific
emerg show dose-depend signific effect across independ endpoint littl correl
confirm treatment effect
posit associ target reduct amyloid pet scan csf biomark clinic respons
support use biomark data trial addit evid
regard high dropout rate think appropri censor miss data use mmrm
random patient arm complet treatment balanc data
endpoint analysi came data infer use mmrm
mmrm valid stat analysi measur compar common method like locf
howev admit measur mmrm patient signific scrutin fda
believ analysi provid addit data support aducanumab regulatori approv
key rational high-dos arm patient enrol chang elig receiv full dose
aducanumab achiev enough drug exposur
median accumul dose mg/kg vs emerge/engag combin week
line enhanc treatment effect subgroup although havent seen cohort
data assum would neg
believ total aducanumab data far support approv earli alzheim despit
limit
compani report svb leerink research estim
aducanumab get approv peak sale
view believ aducanumab could dmt approv treat
alzheim would becom signific product ad
signific unmet need area polit fda want approv
fda involv past summer analyz data encourag file
interact given enough confid start manufactur commerci plan
fda risk reput allow clinic program restart think
would difficult chang cours
physician patient patient advocaci group want drug approv
emerg first dmt trial real success despit caveat
emerg high dose arm show stat sig strongli meaning treatment effect popul
strongli posit studi often enough support approv area high unmet need mani
approv drug space also fail studi dont support efficaci
aducanumab show clear dose respons consist associ abeta/tau
biomark reduct dose-depend imag result clinic respons slow cognit
declin complet trial
high dose arm data impress cohort consid enhanc
treatment effect pbo-adjust cdr-sb reduct emerg move post-
engag move
caveat low dose arm impact also better effect subgroup
aducanumab rel clean safeti profil
overal ae sae rate aducanumab basic similar pbo arm
aria common carrier could manag via titrat control
aria event symptomat often mild-to-moder major patient
aria abl continu treatment resolv advers event week
compani report svb leerink research estim
aducanumab get approv peak sale
physician like strong
physician think reduct vs pbo cdr-sb highli clinic
meaning appreci patient ad commun
physician believ consist efficaci emerg across clinic
valid efficaci endpoint support aducanumab treatment effect
physician believ protocol amend reason wont
bia data analysi
physician indic analysi valid conserv
worri post-futil turnaround ad patient
physician think
analysi
physician think explan regard dose exposur make sens
physician dont like kind post-hoc analysi discourag
statist limit post-hoc analysi analysi appear
consist diseas process
said physician want see detailed/individu data feel
comfort drug profil
physician believ
total aducanumab
data approv
physician think dose-depend signific abeta/p-tau reduct
line aducanumab clinic efficaci data
one physician indic aducanumab approv met
regulatori bar posit pivot trial support trial
physician feel posit come ctad despit uncertainti
one physician note would expect adcom aducanumab
panel may conserv fda
discuss medacorp physician physician svb leerink research
aducanumab get approv peak sale
understand unmet
aducanumab rel
safe well toler
adopt aducanumab
prodrom mild ad
patient ad associ lobbi drug given dmt
approv mani patient aducanumab trial alreadi posit experi
fda involv studi clearli look shoulder
physician think fda would consid signific unmet need approv
aducanumab base strong emerg data
physician worri aria symptomat aria mild moder
physician patient will take ae risk treat ad
physician note aria-h microble tough see without mri thu need
physician note patient may miss micro-hemorrhag diagnosi dont
come back mri may market paus time like
one physician note patient ask question come back onto
drug previous enrol patient probabl restart
treatment durat reimburs physician think aducanumab use
prodromal/mild ad year line clinic trial set would tough
convinc caregiv use advanc ad patient drug test
physician think csf and/or pet test need prodromal/mild ad diagnosi
may becom limit step drug adopt
one physician indic patient practic databas
would meet biomarker/diagnosi criteria elig patient get
ole come
biogen/eisai alreadi work mani pet scan need throughout
countri seem like east west coast alreadi well cover tertiari
center readi diagnost requir monitor
discuss medacorp physician physician svb leerink research
aducanumab get approv peak sale
sale forecast aducanumab
updat deal term eisai
compani report svb leerink research estim
alzheim diseas a-beta mab us us a-beta mab europ ou a-beta mab total total aducanumab deal eisai us eu profit inc
spinraza nusinersen antisens oligonucleotid aso
given intrathec treatment sma pediatr adult patient
what
first approv treatment sma broader fda label initi expect
spinraza restor activ smn protein requir persist motor neuron
under-express sma caus progress neurodegener spinraza improv
product full-length smn protein increas proport mrna transcript
final analysi studi approv
surviv result infantile-onset sma
patient die receiv
patient die
first approv us decemb
establish soc countri formal reimburs countri
multipl composit method use patent us patent expir europ patent
expir howev dont assum gener entri model
forecast us sale declin
forecast ou sale declin
compani report public spinraza fda label svb leerink estim
sustain spinraza given new competit
spinraza face strong competit headwind zolgensma risdiplam
ou sale offer near-term sustain given competit launch time
spinraza differenti competitor either market approv sma
take share novartiss zolgensma one-time-onli gene therapi approv
sma patient year old like patient expect roch
risdiplam oral market leader broader popul sma patient type ii
although apples-to-appl comparison data spinraza zolgensma
risdiplam reveal improv efficaci result competit zolgensma chop-
intend score notabl higher spinraza pre-symptomat sma patient addit
type ii sma zolgensma risdiplam report compar case
physician appreci spinraza first approv sma drug also see one-
time-onli treatment zolgensma simplic daili oral risdiplam potenti
game changer sma treatment landscap
assum spinraza us sale start turn earli zolgensma
uptak increas potenti approv oral risdiplam ou sale pressur
follow zolgensma risdiplam yet approv
launch ramp zolgensma risdiplam import indic patient switch spinraza
expect us sale hit first next year note impact mitig somewhat
expand ou sale given neither zolgensma risdiplam approv region yet
sustain spinraza given new competit
novartiss zolgensma one-time-onli gene therapi approv
sma captur major year old sma patient spinraza
fda approv may fairli broad label
price multipl time higher vs spinraza
zolgensma label includ sma type year age
bi-allel mutat regardless copi
age limit less restrict expect
label allow zolgensma captur type
sma patient without need newborn screen
list price per patient paid year
annual cost per year
assum gross-to-net adjust price
actual net price zolgensma could lower due
mandatori medicaid discount patient
time fail meet outcom measur defin
mechan action differ spinraza
data issu may minor impact
zolgensma base gene therapi design
supplement cell copi gene
rather get neuron produc function smn
protein modul process
transcript spinraza zolgensma
insert function copi gene cell
june fda disclos avexi
inform data manipul issu product test
perform anim zolgensma bla applic
compani indic manipul limit
data manufactur zolgensma
impact interpret clinic data fda
posit assess zolgensma
believ one-tim administr efficaci benefit multipl measur motor function
conveni iv format allow zolgensma becom type sma patient
think data issu may increas fda/ ema scrutini manufactur intrathec form
zolgensma clinic trial approv version zolgensma like stay
market alreadi use success patient
sustain spinraza given new competit
roch risdiplam conveni daili oral captur even share
spinraza type ii sma long maintain compar efficacy/safeti
oral dose advantag spinraza
spinraza market year
think risdiplam shown efficaci similar better
doctor patient see limit
intrathec inject want better option
need special infrastructur team
health provid burden hospit
need larg time commit
physician patients/caregiv need
regularli travel special site
henc daili oral risdiplam welcom chang
spinraza type patient
firefish risdiplam-tr patient
chop intend respond day least
increas vs treat patient endear trial
babi endear trial sat independ
day firefish trial achiev
jan firefish met primari endpoint risdiplam
show statist signific improv infant
type sma safeti find suggest withdraw
similar mechan spinraza differ dose
may captur substanti share type ii sma
risdiplam small molecul splice modul
think risdiplam key threat spinraza
mechan action like spinraza
induc increas product function smn protein
small molecul risdiplam taken oral
much conveni method vs intrathec inject
conveni daili oral dose
may increas smn express outsid
may bring wider benefit bodi tissu
efficacy/safeti profil later data cut
start show improv vs spinraza
risdiplam similar sometim better efficaci safeti conveni administr lower
burden hospital/caregiv caus mani sma type ii patient switch spinraza
risdiplam would like go-to medicin less sever sma patient type ii may
priorit first spinraza first launch
sustain spinraza given new competit
risdiplam zolgensma may superior efficaci vs spinraza longer time
point type ii sma would lead greater use physician spinraza
firefish met primari endpoint jan top-lin
granular data publish yet
thu far zolgensma shown better independ sit
data risdiplam similar spinraza
type ii sma
compani report svb leerink research spinraza zolgensma fda label
chop-intend score
similar to/ slightli better
spinraza shorter timepoint
may indic longer time
horizon efficaci could
better spinraza
risdiplam zolgensma
measur type ii sma
superior spinraza
clinic meaning sma
spinraza endear final result risdiplam firefish part month feb data cut phase march data cut hold head erect without support back left right without support shine open-label extens spinraza endear final result risdiplam firefish open-label month zolgensma phase phase march data cut control endear final result month event-fre score improv score improv score improv last data month -- -chop-intend respons last sit treat month treat sit svb leerink estim poster data event-fre surviv death use perman assist ventil chop-intend respons increas point baselin debat
sustain spinraza given new competit
physician optimist risdiplam compar efficaci spinraza
later-onset sma differ score use make tough compar
type ii sma later-onset
although appl appl comparison physician hope
data indic risdiplam least compar efficaci spinraza
phase endear studi type sma patient hit primari endpoint basi approv
phase cherish studi type ii/iii sma read month prior approv provid support data broad
phase nurtur studi pre-symptomat infant also support earlier treatment spinraza
phase studi pre-symptomat patient open-label phase studi symptomat patient reiter
strong efficaci profil motiv earli use zolgensma infant year old like ahead spinraza
reduc hospit zolgensma-tr patient attract payer patient physician
risdiplam highlight market yet
pivot firefish studi recent met primari endpoint infant type sma treatment-rel safeti issu
relat withdraw
pivot sunfish studi reiter risdiplam promis therapi motor function improv older type ii
unless surpris safeti issu real-world use believ physician eager use zolgensma
risdiplam ahead spinraza base efficaci data
sustain spinraza impact risdiplam target later onset sma
compani report svb leerink research spinraza zolgensma fda label
sustain spinraza given new competit
physician feedback spinraza
patient see benefit
spinraza highli
compliant far
one pediatr neurologist kol note mani patient perceiv benefit
spinraza includ increas rang motion freedom movement
kol mention patient gener believ benefit spinraza
outweigh potenti complic associ repeat lumbar punctur
one neurologist note high degre complianc spinraza among patient
singl patient discontinu treatment kol neurolog center
payer coverag
determin sma
product prefer
one physician doubt payer would will pay costli sma
therapi assum risdiplam also fda approv
one kol indic payer experi spinraza far good
abl get spinraza patient want treatment
posit feedback
spinraza base clinic
experi data
one kol success intrathec administr use ct
guidanc never give sedat kind patient except
famili insist
anoth physician note earlier treatment spinraza better later-stag
patient scoliosi undergon spinal fusion administr
spinraza becom complic risk
physician believ spinraza efficaci type ii sma patient
compel difficult improv later stage diseas
physician view event-fre surviv motor mileston data label
strong especi excit spinraza first approv sma
discuss medacorp physician physician svb leerink research
sustain spinraza given new competit
physician feedback competit landscap
probabl domin
kol cautiou compar efficaci spinraza zolgensma risdiplam
due differ patient baselin characterist think efficaci among drug
gener similar superior yet clear given data
physician believ zolgensma captur elig type pre-symptomat patient
famili would prefer conveni one-tim therapi treatment never
taken away miss famili depend insur access care
indefinit offer lower treatment burden compar repeat intrathec
inject complianc issu lifelong oral regimen
kol think newborn identifi copi receiv zolgensma though
less clear pre-symptomat patient copi patient typic
one kol thought zolgensma ae rate real world would
difficult decis patient base risk/reward assess would
like prefer oral therapi type patient avail
spinraza patient
want switch
risdiplam approv
amount vari us
one eu kol note almost patient would like switch spinraza
risdiplam cours year efficaci safeti profil seen far maintain
convers us-bas kol estim cours year
patient would switch spinraza note mani famili would hesit switch
child improv current stabl spinraza
kol thought like current untreat preval type ii patient
would like start oral therapi spinraza due conveni
eu kol note number stabl type patient put
treatment spinraza specif avoid intrathec inject burden
ae advers event kol key opinion leader ou countri outsid use
discuss medacorp kol physician attend svb leerink research
sustain spinraza given new competit
physician feedback competit landscap
burden felt
physician us
eu could benefit
eu us kol note treatment spinraza creat substanti oper
burden doctor nurs administr staff physic therapi staff
dedic spinraza administr respect treatment center
logist issu spinraza treatment exacerb cold weather month
tough locat hospit bed isol patient respiratori infect sma
patient particularli suscept
physician think treatment burden spinraza like impact physician view
zolgensma risdiplam treat patient latter two agent much easier vs
spinraza intrathec inject burden occupi high degre resourc
immedi use
kol believ combo therapi gene therapi spinraza risdiplam would
use onset treatment due lack relev data possibl payer pushback
kol agre eu us payer like cover use combo therapi
eu kol note expect gene therapi provid truli lifelong
treatment benefit patient would like need maintain either spinraza
risdiplam gene therapi durabl begin wear later year long-term follow-up data
phase start trial show durabl patient year
kol optimist
risdiplam data
present
kol note patient treat firefish sunfish older
progress patient enrol endear cherish former show
numer higher result compar efficaci measur improv
safeti kol like treatment-rel sae report risdiplam
believ overal ae profil risdiplam consist normal seen
sma patient pediatr patient broadli
ae advers event kol key opinion leader ou countri outsid use
discuss medacorp kol physician attend svb leerink research
sustain spinraza given new competit
global sale forecast spinraza indic overal sustain
start erod notabl due competit begin
forecast sale us
use list price per dose gross-
to-net adjust
assum annual price increas
sale estim base manag
discuss medacorp kol call
compani report svb leerink research estim medacorp physician interview
sustain spinraza given new competit
model attribut sotp valu spinraza overal show
global revenu cut half around
global revenu roughli cut half
attribut spinraza
total pt
compani report svb leerink research estim
 risk growth share inc
tecfidera dimethyl fumar vumer diroximel fumar
treatment relaps form multipl sclerosi
what
tecfidera conveni oral dose robust treatment effect year combin clinic
data real-world experi
vumer prodrug tecfidera provid lower gastrointestin side effect
commonli observ tecfidera treatment primarili month decreas time
activ compon drug activ pathway oxid stress reduc slow
progress damag nerv cell
tecfidera vumer phase data rrm
gi teae mild unexpect safeti find
tecfidera approv relaps form ms clinic isol syndrom relapsing-
remit diseas activ secondari progress diseas
vumer approv oct
tecfidera patent expir june patent expir assum loe
vumer composit matter patent expir
tecfidera forecast us sale declin
vumer forecast us sale
compani report public fda label svb leerink research
vumer evolv bid week disabl new year year new year year due gi open-label week tecfidera studi studi vs vs vs pbo endpointvumer evolv week efficaci debat
durabl tecfidera/vumer sale
expect tecfidera gener entri
patent protect tecfidera extra sale
paid assum forward patent dose patent expir
interven patent dose expir
initi method use patent strength dose specif
differ vs claim dose
patent method use patent base invent contribut explicitli dose
phase data kappo show dmf dose treat ms
dose ineffect dose ever test
subsequ phase studi show equival efficaci endpoint
deem unexpect non-linear dose respons support invent contribut
hatch-waxman act district litig initi patent infring proceed multipl
parti west virginia delawar trial set readout
inter part review ipr ipr file patent
coalit ipr institut deni
coalit ipr institut fail invalid patent
feb file juli leverag coalit evid final decis earli feb
sawai sep file march institut sep joinder settl
compani report public svb leerink research
coalit coalit afford drug dmf dimethyl fumar
durabl tecfidera/vumer sale
expect tecfidera gener entri
ipr around patent need prove either dose known work ms
coalit afford drug
previou ipr institut sep
deni establish obvious
kappo studi show fail
district court trial parallel ipr
kappo studi flaw due imbalanc
baselin gd lesion arm recalcul
analysi show signific treatment effect
dose clear dose respons
patent disclos specifi dose
ich guidelin urg dose-respons studi
schimrigk studi patient show
fumaderm also effect treat ms
dose reduct due toler
allow phase studi tecfidera
dmf effect treat psoriasi could
use analog model ms
evid support suffici reason
investig dose
toward effect dose
invalid unexpect featur
prove dose dmf also
efficaci therefor invalid invent
contribut non-linear dose respons dont
gener banner life scienc bafiertam lupin/glenmark gener gain tent fda approv
invalid like incentiv gener player
proactiv settlement recent sawai glenmark
conserv model signific downsid scenario gener entri line ipr
compani report public svb leerink research gd gadolinium
durabl total tecfidera/vumer sale
tecfidera/vumer franchis ms market
vumer launch expect
rx market share us
assum gener entri
share total ms
sensit test us
us tecfidera sale loe
vumer approv rrm safer tecfidera improv gi profil
gi event common earli cours tecfidera treatment month usual decreas time
vumer effect toler option rrm better gi side effect profil vs tecfidera
vumer sale would limit due earli gener tecfidera entri year vumer launch think
could still seiz share ms market delay tecfidera loe could potenti drive addit upsid
compani report public svb leerink estim
valuat tecfidera/vumeritygener entri time inc
durabl ms franchis
view believ remain ms franchis would shrink gradual given
new competit probabl biosimilar entri second half decad
total us trx shrink sinc despit acceler new drug approv
us loe time tysabri avonex plegridi
ou loe time tysabri avonex plegridi
us ms market crowd increas reimburs challeng
new drug approv ms acceler recent year new dmt approv
sale remain durabl expect past year still assum low
single-digit fade biosimilar enter respect product
long-term outlook franchis would also depend loe time key product
dmt diseas modifi therapi ms multipl sclerosi loe loss exclus
durabl royalti biosimilar revenu
expect meaning revenu royalti
part share decreas
gross sale gazyva exce
commerci
pre-tax profit
genentech
develop ocrevu
cll nhl ra
part share decreas
gross sale gazyva exce
mid
us annual
eu year sinc launch
profit share
teva/celltrion truxima approv avail us discount rituxan
juli receiv fda approv second biosimilar rituxan ruxienc
assum ocrevu continu drive signific royalti
may addit product could help off-set base busi eros
earli give credit yet
compani report public svb leerink research
durabl royalti biosimilar revenu
compani report public svb leerink estim
sale share revenu sale sale ocrevu rituxan profit share revenu revenu biosimilar
tanvex biopharma novarti
inta biosimilar coheruss
mylan hulio coheru momenta
boehring bio-thera solut
coheru bioscienc
stada
durabl royalti biosimilar revenu
market pipelin biosimilar product
us au ca
amgen avsola us sorrento
amgen
phase data
commerci right
ulinastatin-fc fusion protein
samsung bioepi joint ventur samsung biolog equiti stake
receiv profit samsung bioepi
commerci right flixabi benepali imraldi make royalti payment imraldi
recent grant global commerci right potenti ophthalmolog biosimilar
well commerci right anti-tnf china
also receiv single-digit royalti samsung bioepi biosimilar use product-specif technolog
compani report public svb leerink research
durabl royalti biosimilar revenu
believ biosimilar market continu grow portfolio continu provid
reliabl revenu compani space becom competit time new
player new product enter market
howev long-term growth trajectori highli depend effici jv need
deliv product pipelin
compani report public svb leerink estim
sale profit sharingsamsung zinbryta eu/canada collabor profit debat
durabl royalti biosimilar revenu
royalti biosimilar revenu sum-of-the-part sotp valuat
compani report public svb leerink estim
royalti risk growth share share expens incom share risk growth share biogen inc
key
valu pipelin
upcom data readout
associ schizophrenia
diversifi pipelin product high-risk/high-reward limit poc data
addit lead abeta asset aducanumab sever anti-tau program
ad phase tango data expect potenti
valid anti-tau moa
data readout genet defin indic strong poc nich
poc proof concept moa mechan action
led season manag team
join evp serv ceo sinc
year leadership experi merck eu china us
receiv certif medicin universit victor segalen
bordeaux ii franc hec school manag pari
serv biogen execut committe sinc decemb
previous serv cfo beacon health option ortho clinic diagnost
boston scientif corpor
hold busi administr univers vermont
 account harvard busi school
serv execut committe sinc serv sinc
held sever senior execut posit sinc join compani
evp
hold human biolog stanford univers harvard
medic school ph neurobiolog harvard univers
sclerosistot tecfidera franchiseassum gener sept growth growth tecfidera growth interferon franchis growth growth growth growth growth growth growth multipl sclerosi growth growth multipl growth biogen inc
growth growth growth growth rate growth growth biosimilar growth rate growth growth sale growth growth excl ad sale eisai growth growth inc
 oper activitiesnet incom oper asset liabil use oper invest activitiescapit market intangibles/aquir busi ionis/samsung consider fumapharma invest use invest financ activitiesnet chang distribut non-control consider incl payment use financ equival begin equival end inc
 balanc sheet receiv current current equip tax stockhold equitycurr liabilitiesaccount payabl accru tax debt current portion lt expens current term tax long term equitypref paid-in comprehens stockhold liabil stockhold biogen inc
